Construct: ORF ccsbBroad304_06575
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF003028.1_s304c1, BRDN0000410190
- Derived from:
- ccsbBroadEn_06575
- DNA Barcode:
- None
- Epitope Tag:
- V5
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- MEF2A (4205)
Vector Information:
- Vector Backbone:
- pLX_304
- Pol II Cassette 1:
- PGK-BlastR
- Pol II Cassette 2:
- CMV-ccsbBroad304_06575
- Selection Marker:
- BlastR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352617.2 | 99.8% | 100% | 873G>A;1494G>T |
| 2 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365207.1 | 99.8% | 100% | 873G>A;1494G>T |
| 3 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_005587.4 | 99.8% | 100% | 873G>A;1494G>T |
| 4 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352618.2 | 99% | 99.2% | 396_407del;885G>A;1506G>T |
| 5 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365206.1 | 99% | 99.2% | 396_407del;885G>A;1506G>T |
| 6 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365203.1 | 98.2% | 98.4% | 865_888del;897G>A;1518G>T |
| 7 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365204.1 | 98.2% | 98.4% | 865_888del;897G>A;1518G>T |
| 8 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521582.2 | 98.2% | 98.4% | 865_888del;897G>A;1518G>T |
| 9 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022191.1 | 98.2% | 98.4% | 865_888del;897G>A;1518G>T |
| 10 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365201.1 | 97.5% | 97.6% | (many diffs) |
| 11 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365202.1 | 97.5% | 97.6% | (many diffs) |
| 12 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521572.2 | 97.5% | 97.6% | (many diffs) |
| 13 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521573.2 | 97.5% | 97.6% | (many diffs) |
| 14 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521577.2 | 97.5% | 97.6% | (many diffs) |
| 15 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521578.2 | 97.5% | 97.6% | (many diffs) |
| 16 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521579.2 | 97.5% | 97.6% | (many diffs) |
| 17 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001130926.2 | 94.8% | 93.7% | (many diffs) |
| 18 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001171894.3 | 94.8% | 93.7% | (many diffs) |
| 19 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352614.2 | 94.8% | 93.7% | (many diffs) |
| 20 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352615.2 | 94.8% | 93.7% | (many diffs) |
| 21 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365208.1 | 94.8% | 93.7% | (many diffs) |
| 22 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001319206.2 | 93.3% | 92.3% | (many diffs) |
| 23 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001352616.2 | 93.3% | 92.3% | (many diffs) |
| 24 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365205.1 | 93.3% | 92.3% | (many diffs) |
| 25 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022195.1 | 86.2% | 86.3% | 52_53ins204;669G>A;1290G>T |
| 26 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521585.2 | 84.2% | 84.3% | (many diffs) |
| 27 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001130928.2 | 83.7% | 80.5% | (many diffs) |
| 28 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521587.2 | 83.7% | 80.5% | (many diffs) |
| 29 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001130927.3 | 82.4% | 79.2% | (many diffs) |
| 30 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365209.1 | 82.4% | 79.2% | (many diffs) |
| 31 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022200.1 | 75% | 75.1% | 0_1ins372;501G>A;1122G>T |
| 32 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022201.1 | 75% | 75.1% | 0_1ins372;501G>A;1122G>T |
| 33 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022199.1 | 74.4% | 74.5% | (many diffs) |
| 34 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022197.2 | 73.8% | 73.9% | (many diffs) |
| 35 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022198.2 | 73.8% | 73.9% | (many diffs) |
| 36 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022196.1 | 73.2% | 73.3% | (many diffs) |
| 37 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_017022202.1 | 70.4% | 70.6% | (many diffs) |
| 38 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_011521590.2 | 58.8% | 57.8% | (many diffs) |
| 39 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XR_001751289.1 | 52.6% | (many diffs) | |
| 40 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365210.2 | 49% | 46.4% | (many diffs) |
| 41 | human | 4205 | MEF2A | myocyte enhancer factor 2A | XM_005254916.3 | 48.6% | 46.1% | (many diffs) |
| 42 | human | 4205 | MEF2A | myocyte enhancer factor 2A | NM_001365211.2 | 44.6% | 40.2% | (many diffs) |
| 43 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291191.1 | 90% | 95.5% | (many diffs) |
| 44 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291192.1 | 90% | 95.5% | (many diffs) |
| 45 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_011250814.2 | 90% | 95.5% | (many diffs) |
| 46 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_006540684.3 | 88.6% | 94% | (many diffs) |
| 47 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_006540685.3 | 88.6% | 94% | (many diffs) |
| 48 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291195.1 | 85% | 89.3% | (many diffs) |
| 49 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001033713.2 | 83.7% | 87.9% | (many diffs) |
| 50 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_006540686.3 | 83.7% | 87.9% | (many diffs) |
| 51 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | XM_017322011.1 | 83.7% | 87.9% | (many diffs) |
| 52 | mouse | 17258 | Mef2a | myocyte enhancer factor 2A | NM_001291196.1 | 63.4% | 67.3% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 66
- ORF end:
- 1563
- ORF length:
- 1497
- Sequence:
-
1 ggtctatata agcagagctc tctggctaac tgtcgggatc aacaagtttg tacaaaaaag 61 ttggcatggg gcggaagaaa atacaaatca cacgcataat ggatgaaagg aaccgacagg 121 tcacttttac aaagagaaag tttggattaa tgaagaaagc ctatgaactt agtgtgctct 181 gtgactgtga aatagcactc atcattttca acagctctaa caaactgttt caatatgcta 241 gcactgatat ggacaaagtt cttctcaagt atacagaata taatgaacct catgaaagca 301 gaaccaactc ggatattgtt gaggctctga acaagaagga acacagaggg tgcgacagcc 361 cagaccctga tacttcatat gtgctaactc cacatacaga agaaaaatat aaaaaaatta 421 atgaggaatt tgataatatg atgcggaatc ataaaatcgc acctggtctg ccacctcaga 481 acttttcaat gtctgtcaca gttccagtga ccagccccaa tgctttgtcc tacactaacc 541 cagggagttc actggtgtcc ccatctttgg cagccagctc aacgttaaca gattcaagca 601 tgctctctcc acctcaaacc acattacata gaaatgtgtc tcctggagct cctcagagac 661 caccaagtac tggcaatgca ggtgggatgt tgagcactac agacctcaca gtgccaaatg 721 gagctggaag cagtccagtg gggaatggat ttgtaaactc aagagcttct ccaaatttga 781 ttggagctac tggtgcaaat agcttaggca aagtcatgcc tacaaagtct ccccctccac 841 caggtggtgg taatcttgga atgaacagta ggaaaccaga tcttcgagtt gtcatccccc 901 cttcaagcaa gggcatgatg cctccactaa atacccaaag gatcagtagt tctcaagcca 961 ctcaacctct tgctacccca gtcgtgtctg tgacaacccc aagcttgcct ccgcaaggac 1021 ttgtgtactc agcaatgccg actgcctaca acactgatta ttcactgacc agcgctgacc 1081 tgtcagccct tcaaggcttc aactcgccag gaatgctgtc gctgggacag gtgtcggcct 1141 ggcagcagca ccacctagga caagcagccc tcagctctct tgttgctgga gggcagttat 1201 ctcagggttc caatttatcc attaatacca accaaaacat cagcatcaag tccgaaccga 1261 tttcacctcc tcgggatcgt atgaccccat cgggcttcca gcagcagcag cagcagcagc 1321 agcagcagca gccgccgcca ccaccgcagc cccagccaca acccccgcag ccccagcccc 1381 gacaggaaat ggggcgctcc cctgtggaca gtctgagcag ctctagtagc tcctatgatg 1441 gcagtgatcg ggaggatcca cggggcgact tccattctcc aattgtgctt ggccgacccc 1501 caaacactga ggacagagaa agcccttctg taaagcgaat gaggatggac gcgtgggtta 1561 cctacccaac tttcttgtac aaagtggttg gtaagcctat ccctaaccct ctcctcggtc 1621 tcgattctac gtagtaatga gctagcgcta accggtggcg cgttaagtcg acaatcaacc 1681 tctggatta